Update on Treatment Strategies in Patients with Non-Alcoholic Fatty Liver DiseasePETTA, Salvatore.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, issn 1381-6128, 159 p.Serial Issue

Pathophysiology of NASH: Perspectives for a Targeted TreatmentMARRA, Fabio; LOTERSZTAJN, Sophie.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5250-5269, issn 1381-6128, 20 p.Article

The Role of Lifestyle Change in the Prevention and Treatment of NAFLDCENTIS, Elena; MARZOCCHI, Rebecca; SUPPINI, Alessandro et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5270-5279, issn 1381-6128, 10 p.Article

Epidemiology and Natural History of Patients with NAFLDBHALA, Neeraj; RAMY IBRAHIM KAMAL JOUNESS; BUGIANESI, Elisabetta et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5169-5176, issn 1381-6128, 8 p.Article

From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic InsightsDE MINICIS, Samuele; DAY, Chris; SVEGLIATI-BARONI, Gianluca et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5239-5249, issn 1381-6128, 11 p.Article

Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLDCARULLI, Lucia; MAURANTONIO, Mauro; HEBBARD, Lionel et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5280-5296, issn 1381-6128, 17 p.Article

Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic TargetMIELE, Luca; MARRONE, Giuseppe; LAURITANO, Cristiano et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5314-5324, issn 1381-6128, 11 p.Article

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to TreatmentDONGIOVANNI, Paola; ANSTEE, Quentin M; VALENTI, Luca et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5219-5238, issn 1381-6128, 20 p.Article

Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver DiseasePETTA, Salvatore; HANDBERG, Aase; CRAXI, Antonio et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5193-5218, issn 1381-6128, 26 p.Article

Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease -Atherosclerosis as a Major Player in the Natural Course of NAFLDLONARDO, Amedeo; SOOKOIAN, Silvia; CHONCHOL, Michel et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5177-5192, issn 1381-6128, 16 p.Article

Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?MUSSO, Giovanni; ANTY, Rodolphe; PETTA, Salvatore et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5297-5313, issn 1381-6128, 17 p.Article